Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 studyNizar M. Tannir, Michael E. Hurwitz, Giovanni Grignani et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 27
Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02Arlene O. Siefker‐Radtke, Nizar M. Tannir, Daniel C. Cho et al.|European Urology|2022Cited by 20
1086 NKTR-288, a polymer-conjugated interferon gamma mutein for the treatment of solid tumorsDamon J. Hamel, Jonathan Zalevsky, Marlene Hennessy et al.|Regular and Young Investigator Award Abstracts|2022Cited by 0